Minovia Therapeutics Receives FDA Orphan Drug Designation for MNV-201 in Myelodysplastic Syndrome
Thursday, October 16, 2025
Minovia Therapeutics has received Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its investigational therapy MNV-201 in Myelodysplastic Syndrome (MDS).
MDS is a group of disorders caused by ineffective blood cell production and genetic instability, often progressing to acute myeloid leukaemia (AML). It primarily affects older adults, with a median age of diagnosis around 70 years. The condition leads to significant health challenges, including anaemia, infection risk, and reduced life expectancy.
Minovia’s MNV-201 is being developed as a first-in-class cell therapy based on the company’s proprietary Mitochondrial Augmentation Technology (MAT). The approach involves introducing healthy, energy-producing mitochondria into a patient’s own stem cells to restore cellular and organ function. Early-stage clinical findings have shown a favourable safety profile and indications of multi-system benefits, including improved muscle function, blood stability, and overall quality of life in patients with Pearson Syndrome.
This designation adds to the company’s existing regulatory recognitions, which include FDA Fast Track Designation for MDS and both Fast Track and Rare Paediatric Disease Designations for the treatment of Pearson Syndrome.
The FDA’s ODD programme aims to support the development of treatments for rare diseases affecting fewer than 200,000 individuals in the United States. The designation provides developers with various incentives such as tax credits, fee waivers, and market exclusivity upon approval.
Minovia is currently conducting a Phase Ib clinical study of MNV-201 in patients with low-risk MDS. Six of the nine planned participants have already been dosed.
The company has also identified novel blood biomarkers that assess mitochondrial health and demonstrated that MDS may have an underlying mitochondrial component, linking it to age-related mitochondrial dysfunction.
Source: globenewswire.com
